Total Payments
$36,588
2023 Payments
$1,800
Companies
4
Transactions
20
Medicare Patients
710
Medicare Billing
$44,350
Payment Breakdown by Category
Research$35,088 (95.9%)
Consulting$1,400 (3.8%)
Food & Beverage$100.07 (0.3%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $35,088 | 17 | 95.9% |
| Consulting Fee | $1,400 | 2 | 3.8% |
| Food and Beverage | $100.07 | 1 | 0.3% |
Payments by Type
Research
$35,088
17 transactions
General
$1,500
3 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Biogen, Inc. | $25,688 | 8 | $0 (2021) |
| Teva Pharmaceuticals USA, Inc. | $8,600 | 10 | $0 (2023) |
| E.R. Squibb & Sons, L.L.C. | $2,200 | 1 | $0 (2017) |
| Telix Pharmaceuticals | $100.07 | 1 | $0 (2022) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2023 | $1,800 | 1 | Teva Pharmaceuticals USA, Inc. ($1,800) |
| 2022 | $100.07 | 1 | Telix Pharmaceuticals ($100.07) |
| 2021 | $3,100 | 1 | Biogen, Inc. ($3,100) |
| 2020 | $5,688 | 2 | Biogen, Inc. ($5,688) |
| 2019 | $11,000 | 2 | Biogen, Inc. ($11,000) |
| 2018 | $8,700 | 7 | Biogen, Inc. ($5,900) |
| 2017 | $6,200 | 6 | Teva Pharmaceuticals USA, Inc. ($4,000) |
All Payment Transactions
20 individual payment records from CMS Open Payments
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 10/25/2023 | Teva Pharmaceuticals USA, Inc. | — | — | Cash or cash equivalent | $1,800.00 | Research |
| Study: TV56286-NDG-20039 | ||||||
| 07/28/2022 | Telix Pharmaceuticals | ILLUCCIX (Drug), ILLUCCIX | Food and Beverage | In-kind items and services | $100.07 | General |
| Category: PROSTATE CANCER THERAPY | ||||||
| 02/04/2021 | Biogen, Inc. | — | — | Cash or cash equivalent | $3,100.00 | Research |
| Study: Phase 2 Study of BIIB092 in Participants With Early Alzheimer's Disease | ||||||
| 02/06/2020 | Biogen, Inc. | — | — | Cash or cash equivalent | $4,443.75 | Research |
| Study: Phase 2 Study of BIIB092 in Participants With Early Alzheimer's Disease | ||||||
| 02/06/2020 | Biogen, Inc. | — | — | Cash or cash equivalent | $1,243.75 | Research |
| Study: Study of BIIB092 in Participants With Progressive Supranuclear Palsy | ||||||
| 03/26/2019 | Biogen, Inc. | — | — | Cash or cash equivalent | $5,550.00 | Research |
| Study: Phase 2 Study of BIIB092 in Participants With Early Alzheimer's Disease | ||||||
| 01/03/2019 | Biogen, Inc. | — | — | Cash or cash equivalent | $5,450.00 | Research |
| Study: Study of BIIB092 in Participants With Progressive Supranuclear Palsy | ||||||
| 10/03/2018 | Biogen, Inc. | — | — | Cash or cash equivalent | $2,600.00 | Research |
| Study: Study of BIIB092 in Participants With Progressive Supranuclear Palsy | ||||||
| 08/22/2018 | Teva Pharmaceuticals USA, Inc. | — | — | Cash or cash equivalent | $600.00 | Research |
| Study: A Multicenter, Multinational, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Laquinimod (0.5, 1.0 and 1.5 mg/Day) as Treatment in Patients With Huntington's Disease | ||||||
| 08/17/2018 | Teva Pharmaceuticals USA, Inc. | — | Consulting Fee | Cash or cash equivalent | $600.00 | General |
| 06/27/2018 | Biogen, Inc. | — | — | Cash or cash equivalent | $1,100.00 | Research |
| Study: Study of BIIB092 in Participants With Progressive Supranuclear Palsy | ||||||
| 05/30/2018 | Teva Pharmaceuticals USA, Inc. | — | — | Cash or cash equivalent | $800.00 | Research |
| Study: A Multicenter, Multinational, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Laquinimod (0.5, 1.0 and 1.5 mg/Day) as Treatment in Patients With Huntington's Disease | ||||||
| 05/09/2018 | Biogen, Inc. | — | — | Cash or cash equivalent | $2,200.00 | Research |
| Study: Study of BIIB092 in Participants With Progressive Supranuclear Palsy | ||||||
| 03/05/2018 | Teva Pharmaceuticals USA, Inc. | — | Consulting Fee | Cash or cash equivalent | $800.00 | General |
| 12/13/2017 | Teva Pharmaceuticals USA, Inc. | Laquinimod (Drug) | — | Cash or cash equivalent | $800.00 | Research |
| Study: TV5600-CNS-20007 • Category: Neurology | ||||||
| 09/20/2017 | Teva Pharmaceuticals USA, Inc. | Laquinimod (Drug) | — | Cash or cash equivalent | $800.00 | Research |
| Study: TV5600-CNS-20007 • Category: Neurology | ||||||
| 06/21/2017 | Teva Pharmaceuticals USA, Inc. | Laquinimod (Drug) | — | Cash or cash equivalent | $800.00 | Research |
| Study: TV5600-CNS-20007 • Category: Neurology | ||||||
| 05/27/2017 | E.R. Squibb & Sons, L.L.C. | — | — | Cash or cash equivalent | $2,200.00 | Research |
| Study: Study of BMS 986168 in Patients With Progressive Supranuclear Palsy PASSPORT | ||||||
| 04/12/2017 | Teva Pharmaceuticals USA, Inc. | Laquinimod (Drug) | — | Cash or cash equivalent | $800.00 | Research |
| Study: TV5600-CNS-20007 • Category: Neurology | ||||||
| 01/18/2017 | Teva Pharmaceuticals USA, Inc. | Laquinimod (Drug) | — | Cash or cash equivalent | $800.00 | Research |
| Study: TV5600-CNS-20007 • Category: Neurology | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| Phase 2 Study of BIIB092 in Participants With Early Alzheimer's Disease | Biogen, Inc. | $13,094 | 3 |
| Study of BIIB092 in Participants With Progressive Supranuclear Palsy | Biogen, Inc. | $12,594 | 5 |
| TV5600-CNS-20007 | Teva Pharmaceuticals USA, Inc. | $4,000 | 5 |
| Study of BMS 986168 in Patients With Progressive Supranuclear Palsy PASSPORT | E.R. Squibb & Sons, L.L.C. | $2,200 | 1 |
| TV56286-NDG-20039 | Teva Pharmaceuticals USA, Inc. | $1,800 | 1 |
| A Multicenter, Multinational, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Laquinimod (0.5, 1.0 and 1.5 mg/Day) as Treatment in Patients With Huntington's Disease | Teva Pharmaceuticals USA, Inc. | $1,400 | 2 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 5 | 172 | 188 | $34,860 | $12,738 |
| 2022 | 5 | 166 | 178 | $23,075 | $10,287 |
| 2021 | 4 | 185 | 199 | $22,527 | $12,042 |
| 2020 | 3 | 187 | 195 | $23,054 | $9,283 |
Total Patients
710
Total Services
760
Medicare Billing
$44,350
Procedure Codes
25
All Medicare Procedures & Services
25 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 52 | 57 | $7,318 | $3,855 | 52.7% |
| 99222 | Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | Facility | 2023 | 21 | 21 | $8,121 | $2,226 | 27.4% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 23 | 23 | $5,277 | $1,995 | 37.8% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2023 | 24 | 28 | $5,620 | $1,796 | 32.0% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 12 | 18 | $3,791 | $1,155 | 30.5% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 25 | 25 | $2,127 | $1,069 | 50.3% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2023 | 15 | 16 | $2,606 | $641.64 | 24.6% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 35 | 37 | $4,622 | $2,176 | 47.1% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 38 | 40 | $3,442 | $1,960 | 56.9% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2022 | 26 | 29 | $3,771 | $1,599 | 42.4% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2022 | 33 | 38 | $3,642 | $1,549 | 42.5% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 12 | 12 | $2,688 | $1,275 | 47.4% |
| 99222 | Initial hospital inpatient care per day, typically 50 minutes | Facility | 2022 | 11 | 11 | $3,997 | $1,243 | 31.1% |
| 99442 | Telephone medical discussion with physician, 11-20 minutes | Office | 2022 | 11 | 11 | $913.00 | $485.47 | 53.2% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 56 | 61 | $7,320 | $4,270 | 58.3% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 38 | 41 | $3,508 | $2,091 | 59.6% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Facility | 2021 | 27 | 30 | $3,600 | $2,054 | 57.0% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Facility | 2021 | 33 | 35 | $3,000 | $1,461 | 48.7% |
| 99204 | New patient outpatient visit, total time 45-59 minutes | Office | 2021 | 14 | 14 | $3,255 | $1,448 | 44.5% |
| 99442 | Physician telephone patient service, 11-20 minutes of medical discussion | Office | 2021 | 17 | 18 | $1,844 | $718.26 | 39.0% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 52 | 58 | $7,050 | $2,697 | 38.3% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Facility | 2020 | 32 | 33 | $4,307 | $2,090 | 48.5% |
| 99213 | Established patient office or other outpatient visit, typically 15 minutes | Office | 2020 | 49 | 50 | $4,659 | $1,684 | 36.1% |
| 99213 | Established patient office or other outpatient visit, typically 15 minutes | Facility | 2020 | 38 | 38 | $3,335 | $1,549 | 46.4% |
| 99204 | New patient office or other outpatient visit, typically 45 minutes | Office | 2020 | 16 | 16 | $3,703 | $1,264 | 34.1% |
About Dr. Roger Albin, MD
Dr. Roger Albin, MD is a Neurology healthcare provider based in Ann Arbor, Michigan. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 10/11/2006. The National Provider Identifier (NPI) number assigned to this provider is 1568551422.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Roger Albin, MD has received a total of $36,588 in payments from pharmaceutical and medical device companies, with $1,800 received in 2023. These payments were reported across 20 transactions from 4 companies. The most common payment nature is "" ($35,088).
As a Medicare-enrolled provider, Albin has provided services to 710 Medicare beneficiaries, totaling 760 services with total Medicare billing of $44,350. Data is available for 4 years (2020–2023), covering 25 distinct procedure/service records.
Ad
Practice Information
- Specialty Neurology
- Location Ann Arbor, MI
- Active Since 10/11/2006
- Last Updated 01/17/2012
- Taxonomy Code 2084N0400X
- Entity Type Individual
- NPI Number 1568551422
Products in Payments
- Laquinimod (Drug) $4,000
- ILLUCCIX (Drug) $100.07
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Neurology Doctors in Ann Arbor
Wade Cooper, Do, DO
Neurology — Payments: $692,532
Neurology $692,532
James Weintraub, D.o, D.O
Neurology — Payments: $310,749
Neurology $310,749
Matthew Lorincz, Md, MD
Neurology — Payments: $36,085
Neurology $36,085
Dr. Denise Leung, M.d, M.D
Neurology — Payments: $20,721
Neurology $20,721
Dawn Kleindorfer, Md, MD
Neurology — Payments: $13,978
Neurology $13,978
Charles Schultz, Md, MD
Neurology — Payments: $8,851
Neurology $8,851